Optima Medical Innovations Corp. (OMIC)
Feb 21, 2025 - OMIC was delisted (reason: acquired by Deerfield)
20.01
0.00 (0.00%)
Inactive · Last trade price on Feb 20, 2025
Singular Genomics Systems Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
Period Ending | Sep '21 Sep 30, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
| 1.94 | 4.61 | 5.37 | 0.73 | 0.39 | 0.48 | |
Revenue Growth | -72.87% | -14.09% | 633.40% | 85.81% | -18.05% | - |
Cost of Revenue | 1.55 | 3.23 | 3.66 | 0.76 | 0.26 | 0.44 |
Gross Profit | 0.39 | 1.38 | 1.71 | -0.03 | 0.14 | 0.04 |
Selling, General & Admin | -0.42 | 2.11 | 4.18 | 4.68 | 5.69 | 1.14 |
Research & Development | 0.03 | 0.1 | 0.03 | 0.07 | - | - |
Operating Expenses | 0.21 | 3.67 | 8.65 | 7.77 | 5.75 | 1.18 |
Operating Income | 0.18 | -2.29 | -6.94 | -7.79 | -5.62 | -1.14 |
Interest Expense | -0.19 | -0.21 | -0.22 | -0.01 | -0.25 | -0.09 |
Interest & Investment Income | 0 | 0 | 0.02 | - | - | - |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | - | - | - |
Other Non Operating Income (Expenses) | -0.03 | -1.01 | - | 0.05 | - | - |
EBT Excluding Unusual Items | -0.05 | -3.51 | -7.14 | -7.75 | -5.86 | -1.23 |
Merger & Restructuring Charges | - | - | - | -3.38 | - | - |
Impairment of Goodwill | - | - | -5.56 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | -1.12 | -0.99 | - | - |
Gain (Loss) on Sale of Assets | 1.68 | 1.68 | - | - | - | - |
Asset Writedown | -1.99 | -1.99 | -3.82 | - | - | - |
Legal Settlements | -0.18 | -0.18 | - | - | - | - |
Other Unusual Items | 0.17 | 0.03 | - | -3.57 | - | - |
Pretax Income | -0.37 | -3.96 | -17.63 | -15.7 | -5.86 | -1.23 |
Net Income | -0.37 | -3.96 | -17.63 | -15.7 | -5.86 | -1.23 |
Net Income to Common | -0.37 | -3.96 | -17.63 | -15.7 | -5.86 | -1.23 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 51 | 49 | 43 | 14 | 6 | 2 |
Shares Outstanding (Diluted) | 51 | 49 | 43 | 14 | 6 | 2 |
Shares Change | 7.51% | 13.12% | 201.33% | 136.49% | 142.58% | - |
EPS (Basic) | -0.01 | -0.08 | -0.41 | -1.10 | -0.97 | -0.49 |
EPS (Diluted) | -0.01 | -0.08 | -0.41 | -1.10 | -0.97 | -0.49 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
Period Ending | Sep '21 Sep 30, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
Free Cash Flow | 0.21 | -0.31 | -2.43 | -2.09 | -1.75 | -0.7 |
Free Cash Flow Per Share | 0.00 | -0.01 | -0.06 | -0.15 | -0.29 | -0.28 |
Gross Margin | 20.19% | 29.93% | 31.87% | -3.80% | 34.89% | 7.61% |
Operating Margin | 9.29% | -49.59% | -129.19% | -1064.40% | -1424.87% | -237.12% |
Profit Margin | -18.81% | -85.86% | -328.33% | -2144.60% | -1487.38% | -254.89% |
Free Cash Flow Margin | 10.61% | -6.72% | -45.24% | -284.82% | -443.41% | -144.77% |
EBITDA | 0.59 | -1.73 | -5.81 | -7.61 | -5.55 | -1.1 |
EBITDA Margin | 30.41% | -37.60% | -108.28% | - | - | -229.19% |
D&A For EBITDA | 0.41 | 0.55 | 1.12 | 0.18 | 0.07 | 0.04 |
EBIT | 0.18 | -2.29 | -6.94 | -7.79 | -5.62 | -1.14 |
EBIT Margin | 9.29% | -49.59% | -129.19% | - | - | -237.12% |
Revenue as Reported | 1.94 | 4.61 | 5.37 | 0.73 | - | - |